Triple
T1168586
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Eli Lilly and Company |
E24856
|
entity |
| Predicate | hasSubsidiary |
P254
|
FINISHED |
| Object |
Loxo Oncology (acquired)
Loxo Oncology (acquired) is a biotechnology company focused on developing targeted cancer therapies, particularly for tumors driven by specific genetic alterations.
|
E133655
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69a494082a7c819095004f423f294a64 |
elicitation | completed |
| NER | batch_69a4bccef84481908864e819884af86c |
ner | completed |
| NED1 | batch_69ac668562788190ac5f8d081a46b2ee |
ned_source_triple | completed |
| NED2 | batch_69ac6826ef4c81909fc077bfba22b16f |
ned_description | completed |
| NEDg | batch_69ac67a07f28819096fcd7b767e07a63 |
nedg | completed |
Created at: March 1, 2026, 7:45 p.m.